Cabozantinib (2 brand names, 1 dosage form, 1 route)
Available dosage forms: TABLET.
Routes of administration: ORAL.
Brand Names
- CABOZANTINIB
- RESNIBEN
Indications and Usage
COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
Contraindications
None
Adverse Reactions
The following clinically significant adverse reactions are discussed elsewhere in the labeling: Perforations and Fistula [see Warnings and Precautions (5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Thromboembolic Events [see Warnings and Precautions (5.3)] Impaired Wound Healing [see Warnings and Precautions (5.4)] Hypertension and Hypertensive Crisis [see Warnings and Precautions (5.5)] Cardiac Failure [see Warnings and Precautions (5.6)] Osteonecrosis of the Jaw [see Warnings and Precautions (5.7)] Diarrhea [see Warnings and Precautions (5.8)] Palmar-Plantar Erythrodysesthesia [see Warnings and Precautions (5.9)] Proteinuria [see Warnings and Precautions (5.10)] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.11)] Hypocalcemia [see Warnings and Precautions (5.13)]
Mechanism of Action
In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Overdosage
One case of overdosage was reported in a patient who inadvertently took twice the intended dose (200 mg daily) for nine days. The patient suffered Grade 3 memory impairment, Grade 3 mental status changes, Grade 3 cognitive disturbance, Grade 2 weight loss, and Grade 1 increase in BUN. The extent of recovery was not documented.